AI Article Synopsis
- Pediatric patients awaiting heart transplants have seen survival rates improve with the use of pediatric-specific ventricular assist devices, but neonates and infants still face high mortality rates on waitlists.
- The Berlin Heart EXCOR is the only long-term device approved in the U.S. but has limitations due to its pulsatile design.
- A review of Stanford's experience showed varying survival rates among different patient groups, prompting modifications in treatment protocols to enhance outcomes, alongside the upcoming PumpKIN trial testing new technology.
Article Abstract
Heart transplant waitlist survival in pediatric patients has been substantially improved since the introduction of pediatric-specific ventricular assist device. In neonates and infants, however, the waitlist mortality remains very high. The only long-term device currently approved for use in the United States is the Berlin Heart EXCOR, but this device has several important limitations because of the paracorporeal, pulsatile nature of the underlying technology. We reviewed Stanford ventricular assist experience on patients less than 1 year old since 2004. It shows overall 1-, 3-, and 5-year survival were 68%, 62%, and 49%, respectively. There are statistically significant differences in survival among cardiomyopathy group, end-stage congenital heart disease group and single ventricle group. In order to improve outcomes in this extremely high risk group, modifications were made to anticoagulation protocols, cannulation strategy in hypertrophic cardiomyopathy patients, and preferential use of continuous flow pumps in a single ventricle patients. The long-waited PumpKIN trial testing the Jarvik 2015 is about to start with the first human implant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.pcsu.2017.11.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apixaban Anticoagulation in HeartMate 3 Left Ventricular Assist Device: A Meta-Analysis of Randomized Controlled Trials.
ASAIO J
January 2025
From the Intensive Cardiac Care Unit, Cardiology Department, Rangueil University Hospital, Toulouse, France.
Assessment of hemodynamic disturbances and impaired ventricular filling in asymptomatic fontan patients: A 4D flow CMR study.
Eur J Radiol Open
June 2025
Department of Radiology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dong Fang Road, Shanghai 200127, PR China.
Background: The Fontan procedure is a surgical intervention designed for patients with single ventricle physiology, wherein the systemic venous return is redirected into the pulmonary circulation, thereby facilitating passive pulmonary blood flow without the assistance of ventricular propulsion. Consequently, long-term follow-up of individuals who have undergone the asymptomatic Fontan procedure is essential.
Objectives: The aims of this investigation were to: 1) examine the impact of flow components and kinetic energy (KE) parameters on hemodynamic disturbances in asymptomatic Fontan patients and control group; 2) Assess left ventricular diastolic dysfunction through the analysis of 4D flow parameters across different Fontan sub-groups; 3) Compare intracardiac flow parameters among Fontan sub-groups based on morphological features of the left ventricle (LV) and right ventricle (RV).
Risk Estimation of Severe Primary Graft Dysfunction in Heart Transplant Recipients Using a Smartphone.
Rev Cardiovasc Med
January 2025
Cardiac Surgery, Lausanne University Hospital CHUV Lausanne, 1011 Lausanne, Switzerland.
Background: Currently, there are no standardized guidelines for graft allocation in heart transplants (HTxs), particularly when considering organs from marginal donors and donors after cardiocirculatory arrest. This complexity highlights the need for an effective risk analysis tool for primary graft dysfunction (PGD), a severe complication in HTx. Existing score systems for predicting PGD lack superior predictive capability and are often too complex for routine clinical use.
View Article and Find Full Text PDFRecent Developments in Ventricular Assist Device Therapy.
Rev Cardiovasc Med
January 2025
Center for Preclinical Surgical & Interventional Research, The Texas Heart Institute, Houston, TX 77030, USA.
The evolution of left ventricular assist devices (LVADs) from large, pulsatile systems to compact, continuous-flow pumps has significantly improved implantation outcomes and patient mobility. Minimally invasive surgical techniques have emerged that offer reduced morbidity and enhanced recovery for LVAD recipients. Innovations in wireless power transfer technologies aim to mitigate driveline-related complications, enhancing patient safety and quality of life.
View Article and Find Full Text PDFAssociation between neutrophil-to-lymphocyte ratio and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus.
Front Endocrinol (Lausanne)
January 2025
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Diabetes has become a global pandemic, posing a sustained threat to human health, primarily due to its associated complications. Left ventricular diastolic dysfunction (LVDD) is a prevalent cardiac complication among patients with diabetes. Since most patients are asymptomatic and lack relevant biomarkers, LVDD has not attracted significant attention from clinicians.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!